<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Lesson 16.6: Cognitive Decline: Integrating the Bredesen Protocol for Early MCI</title>
    <style>
        /* Base & Reset */
        * {
            box-sizing: border-box;
        }

        body {
            font-family: Georgia, 'Times New Roman', serif;
            line-height: 1.8;
            color: #2d2d2d;
            background: #f8f6f3;
            margin: 0;
            padding: 0;
        }

        /* Main Container */
        .lesson-container {
            max-width: 860px;
            margin: 0 auto;
            padding: 40px 30px;
            background: #ffffff;
            min-height: 100vh;
            box-shadow: 0 0 60px rgba(0, 0, 0, 0.08);
        }

        /* Brand Header */
        .brand-header {
            text-align: center;
            padding-bottom: 30px;
            margin-bottom: 35px;
            border-bottom: 1px solid #eee;
        }

        .brand-logo {
            max-width: 220px;
            height: auto;
            margin-bottom: 5px;
        }

        /* Module Header - DEEP BLUE/PURPLE theme for Neuroscience/Advanced Cases */
        .module-header {
            background: linear-gradient(135deg, #1e3a8a 0%, #3b82f6 100%);
            padding: 35px 35px 30px;
            border-radius: 16px;
            margin-bottom: 30px;
            position: relative;
            overflow: hidden;
        }

        .module-header::before {
            content: '';
            position: absolute;
            top: 0;
            right: 0;
            width: 300px;
            height: 300px;
            background: radial-gradient(circle, rgba(255, 255, 255, 0.1) 0%, transparent 70%);
            transform: translate(100px, -100px);
        }

        .module-header::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 100%;
            height: 4px;
            background: linear-gradient(90deg, #B8860B, #D4A84B, #B8860B);
        }

        .module-label {
            margin: 0;
            font-size: 11px;
            color: rgba(255, 255, 255, 0.75);
            text-transform: uppercase;
            letter-spacing: 2.5px;
            font-weight: 500;
        }

        .lesson-title {
            margin: 10px 0 0 0;
            font-size: 28px;
            color: #ffffff;
            font-weight: 700;
            line-height: 1.3;
            position: relative;
        }

        .lesson-meta {
            display: flex;
            gap: 12px;
            margin-top: 20px;
            padding-top: 18px;
            border-top: 1px solid rgba(255, 255, 255, 0.15);
            flex-wrap: wrap;
        }

        .meta-item {
            display: flex;
            align-items: center;
            gap: 6px;
            font-size: 12px;
            color: rgba(255, 255, 255, 0.85);
            background: rgba(255, 255, 255, 0.1);
            padding: 5px 12px;
            border-radius: 4px;
        }

        /* Table of Contents */
        .toc-box {
            background: linear-gradient(135deg, #fafafa 0%, #f5f5f5 100%);
            border-radius: 14px;
            padding: 24px 28px;
            margin-bottom: 35px;
            border: 1px solid #e8e8e8;
        }

        .toc-box .box-label {
            font-weight: 600;
            color: #1e3a8a;
            margin: 0 0 18px 0;
            font-size: 12px;
            text-transform: uppercase;
            letter-spacing: 2px;
            padding-bottom: 12px;
            border-bottom: 1px solid #e0e0e0;
        }

        .toc-list {
            list-style: none;
            margin: 0;
            padding: 0;
            display: grid;
            grid-template-columns: repeat(2, 1fr);
            gap: 8px 24px;
        }

        .toc-list li {
            margin: 0;
        }

        .toc-list a {
            display: flex;
            align-items: center;
            padding: 8px 12px;
            color: #555;
            text-decoration: none;
            font-size: 14px;
            border-radius: 6px;
            transition: all 0.2s ease;
        }

        .toc-list a:hover {
            background: white;
            color: #1e3a8a;
            box-shadow: 0 2px 8px rgba(0, 0, 0, 0.06);
        }

        .toc-list .section-num {
            display: inline-flex;
            align-items: center;
            justify-content: center;
            width: 26px;
            height: 26px;
            background: #1e3a8a;
            color: white;
            font-weight: 600;
            font-size: 11px;
            border-radius: 6px;
            margin-right: 12px;
            flex-shrink: 0;
        }

        /* Learning Objectives */
        .objectives-box {
            background: #eff6ff;
            border: 2px solid #3b82f6;
            border-radius: 14px;
            padding: 30px 35px;
            margin-bottom: 40px;
        }

        .objectives-box .box-label {
            font-weight: 600;
            color: #1e3a8a;
            margin: 0 0 18px 0;
            font-size: 13px;
            text-transform: uppercase;
            letter-spacing: 2px;
            display: flex;
            align-items: center;
            gap: 10px;
        }

        .objectives-box .box-label::before {
            content: 'üéØ';
            font-size: 18px;
        }

        .objectives-box ul {
            margin: 0;
            padding-left: 22px;
        }

        .objectives-box li {
            margin-bottom: 14px;
            font-size: 16px;
            line-height: 1.7;
        }

        /* Section Headings */
        h2 {
            font-size: 24px;
            color: #1e3a8a;
            margin: 50px 0 20px 0;
            font-weight: 600;
            position: relative;
            padding-bottom: 12px;
        }

        h2::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 60px;
            height: 3px;
            background: #B8860B;
        }

        h3 {
            font-size: 20px;
            color: #2563eb;
            margin: 35px 0 15px 0;
            font-weight: 600;
        }

        /* Paragraphs & Highlighting */
        p {
            font-size: 17px;
            margin-bottom: 20px;
            color: #333;
        }

        .highlight {
            background: linear-gradient(180deg, transparent 60%, #FFF59D 60%);
            padding: 0 4px;
            font-weight: 500;
        }

        /* Statistics Box */
        .stats-box {
            background: linear-gradient(135deg, #1e3a8a 0%, #2563eb 100%);
            padding: 40px;
            border-radius: 16px;
            margin: 35px 0;
            position: relative;
            overflow: hidden;
            color: white;
        }

        .stats-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(140px, 1fr));
            gap: 25px;
            position: relative;
        }

        .stat-item {
            text-align: center;
        }

        .stat-number {
            font-size: 42px;
            font-weight: 700;
            line-height: 1;
            margin-bottom: 8px;
        }

        .stat-label {
            font-size: 13px;
            color: rgba(255, 255, 255, 0.85);
            text-transform: uppercase;
            letter-spacing: 1px;
        }

        /* Case Study Box */
        .case-study {
            background: linear-gradient(135deg, #f8f9fb 0%, #f0f2f5 100%);
            border-radius: 16px;
            padding: 0;
            margin: 40px 0;
            overflow: hidden;
            box-shadow: 0 4px 20px rgba(0, 0, 0, 0.06);
            border: 1px solid #e5e7eb;
        }

        .case-study-header {
            background: linear-gradient(135deg, #1e3a8a 0%, #3b82f6 100%);
            padding: 20px 30px;
            display: flex;
            align-items: center;
            gap: 15px;
        }

        .case-study-header .box-label {
            font-weight: 600;
            color: #ffffff;
            margin: 0;
            font-size: 16px;
        }

        .case-study-content {
            padding: 28px 30px;
        }

        .patient-profile {
            display: flex;
            align-items: center;
            gap: 18px;
            padding: 18px 22px;
            background: white;
            border-radius: 12px;
            margin-bottom: 20px;
            border: 1px solid #e5e5e5;
        }

        .patient-avatar {
            width: 55px;
            height: 55px;
            background: #3b82f6;
            color: white;
            border-radius: 50%;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 24px;
        }

        /* Data Tables */
        .data-table-container {
            margin: 30px 0;
            overflow-x: auto;
            border-radius: 12px;
            border: 1px solid #e5e7eb;
        }

        table {
            width: 100%;
            border-collapse: collapse;
            font-size: 15px;
            text-align: left;
        }

        th {
            background: #f1f5f9;
            padding: 15px;
            font-weight: 600;
            color: #1e3a8a;
            border-bottom: 2px solid #e5e7eb;
        }

        td {
            padding: 15px;
            border-bottom: 1px solid #f1f5f9;
            color: #444;
        }

        /* Check Understanding */
        .check-understanding {
            background: #fffaf0;
            border: 2px solid #B8860B;
            border-radius: 16px;
            padding: 32px;
            margin: 45px 0;
        }

        .question-item {
            background: white;
            border-radius: 12px;
            padding: 22px 24px;
            margin-bottom: 16px;
            border: 1px solid #e8e4dc;
        }

        .reveal-btn {
            background: #1e3a8a;
            color: white;
            border: none;
            padding: 10px 20px;
            border-radius: 8px;
            cursor: pointer;
        }

        .answer-text {
            display: none;
            margin-top: 15px;
            padding: 15px;
            background: #f0fdf4;
            border-radius: 8px;
            color: #166534;
        }

        /* Takeaways & References */
        .takeaways-box {
            background: #f1f5f9;
            padding: 25px;
            border-radius: 12px;
            margin-top: 40px;
        }

        .references-box {
            margin-top: 40px;
            padding: 25px;
            background: #fafafa;
            border-top: 1px solid #eee;
            font-size: 14px;
        }

        .references-box h4 {
            margin-top: 0;
            color: #666;
        }

        .references-list {
            list-style: none;
            padding: 0;
        }

        .references-list li {
            margin-bottom: 8px;
            color: #777;
        }

        .lesson-footer {
            text-align: center;
            margin-top: 60px;
            padding-bottom: 40px;
        }

        .highlight-blue {
            color: #2563eb;
            font-weight: 600;
        }
    </style>
</head>

<body>
    <div class="lesson-container">
        <div class="brand-header">
            <img src="https://accredipro.com/wp-content/uploads/2023/05/AccrediPro-Logo-Horizontal-1.png" alt="AccrediPro Academy" class="brand-logo">
        </div>

        <header class="module-header">
            <p class="module-label">Module 16: Advanced Case Studies</p>
            <h1 class="lesson-title">Lesson 6: Cognitive Decline: Integrating the Bredesen Protocol for Early MCI</h1>
            <div class="lesson-meta">
                <span class="meta-item">‚è±Ô∏è 35 min read</span>
                <span class="meta-item">üéì Advanced Certification Level</span>
            </div>
        </header>

        <div class="toc-box">
            <p class="box-label">In This Lesson</p>
            <ul class="toc-list">
                <li><a href="#paradigm"><span class="section-num">1</span>The Synaptoblastic Shift</a></li>
                <li><a href="#subtypes"><span class="section-num">2</span>The Six Subtypes of Alzheimer's</a></li>
                <li><a href="#data"><span class="section-num">3</span>Data-Driven Biomarker Targets</a></li>
                <li><a href="#ketoflex"><span class="section-num">4</span>KetoFLEX 12/3 Framework</a></li>
                <li><a href="#apoe4"><span class="section-num">5</span>ApoE4 & Individualized Care</a></li>
                <li><a href="#guide"><span class="section-num">6</span>Guiding the Cognitive Journey</a></li>
            </ul>
        </div>

        <div class="objectives-box">
            <p class="box-label">Learning Objectives</p>
            <ul>
                <li>Master the identification of the six distinct subtypes of cognitive decline using Root Cause Analysis.</li>
                <li>Apply the KetoFLEX 12/3 nutritional framework to restore metabolic flexibility and mitochondrial function.</li>
                <li>Interpret advanced biomarkers (Homocysteine, Insulin, Vitamin D) through the lens of cognitive optimization.</li>
                <li>Develop individualized protocols for ApoE4 carriers, focusing on lipid metabolism and detoxification.</li>
                <li>Implement a multi-modal "Guide the Journey" strategy involving brain training, sleep hygiene, and MBSR.</li>
            </ul>
        </div>

        <h2 id="paradigm">1. The Synaptoblastic Shift: Beyond Amyloid-Beta</h2>
        <p>For decades, conventional neurology has viewed Alzheimer‚Äôs Disease (AD) and Mild Cognitive Impairment (MCI) through the lens of the "Amyloid Hypothesis"‚Äîthe idea that amyloid-beta plaques are the primary cause of decline. However, the <span class="highlight">B.R.I.D.G.E. Method‚Ñ¢</span> shifts this paradigm, viewing amyloid not as the "villain," but as a protective response to metabolic, inflammatory, or toxic insults.</p>

        <p>In this integrative model, we distinguish between <span class="highlight-blue">synaptoclastic</span> (synapse-destroying) and <span class="highlight-blue">synaptoblastic</span> (synapse-building) signaling. Cognitive decline occurs when the balance tips toward synaptoclasis. Our goal as practitioners is to identify the "holes in the roof"‚Äîthe various drivers causing this imbalance‚Äîand patch them simultaneously.</p>

        <div class="stats-box">
            <div class="stats-grid">
                <div class="stat-item">
                    <div class="stat-number">84%</div>
                    <div class="stat-label">Improvement Rate in Bredesen Study</div>
                </div>
                <div class="stat-item">
                    <div class="stat-number">36+</div>
                    <div class="stat-label">Potential Metabolic Drivers</div>
                </div>
                <div class="stat-item">
                    <div class="stat-number">10-20y</div>
                    <div class="stat-label">Pre-symptomatic Window</div>
                </div>
            </div>
        </div>

        <h2 id="subtypes">2. Root Cause Analysis: The Six Subtypes</h2>
        <p>Dr. Dale Bredesen's research has categorized cognitive decline into six primary subtypes. Identifying these is crucial for <span class="highlight">Individualized Care</span>, as a Type 1 protocol differs significantly from a Type 3 protocol.</p>

        <div class="data-table-container">
            <table>
                <thead>
                    <tr>
                        <th>Subtype</th>
                        <th>Name</th>
                        <th>Primary Driver</th>
                        <th>Key Biomarkers</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>Type 1</td>
                        <td>Inflammatory (Hot)</td>
                        <td>Systemic inflammation</td>
                        <td>hs-CRP > 1.0, Albumin/Globulin ratio < 1.5</td>
                    </tr>
                    <tr>
                        <td>Type 1.5</td>
                        <td>Glycotoxic (Sweet)</td>
                        <td>Insulin resistance + Inflammation</td>
                        <td>HbA1c > 5.5%, Fasting Insulin > 4.5</td>
                    </tr>
                    <tr>
                        <td>Type 2</td>
                        <td>Atrophic (Cold)</td>
                        <td>Lack of trophic support</td>
                        <td>Low Vit D, B12, Hormones (T3, Estradiol)</td>
                    </tr>
                    <tr>
                        <td>Type 3</td>
                        <td>Toxic (Vile)</td>
                        <td>Metals, Mycotoxins, Chemicals</td>
                        <td>Low Zinc, High C4a, MARCoNS+</td>
                    </tr>
                    <tr>
                        <td>Type 4</td>
                        <td>Vascular (Pale)</td>
                        <td>Reduced cerebral blood flow</td>
                        <td>Abnormal carotid ultrasound, high LDL-p</td>
                    </tr>
                    <tr>
                        <td>Type 5</td>
                        <td>Traumatic (Dazed)</td>
                        <td>History of TBI/Concussion</td>
                        <td>Clinical history, high NFL (Neurofilament light)</td>
                    </tr>
                </tbody>
            </table>
        </div>

        <h2 id="data">3. Data-Driven Decisions: Precision Biomarkers</h2>
        <p>In the <span class="highlight">Data-Driven Decisions</span> phase, we move beyond the "normal" lab ranges to "optimal" ranges required for neuro-regeneration. A 2021 study published in the <i>Journal of Alzheimer's Disease</i> demonstrated that participants who achieved these specific targets showed significant improvement in MoCA (Montreal Cognitive Assessment) scores.</p>

        <h3>Critical Neuro-Metabolic Targets:</h3>
        <ul>
            <li><strong>Homocysteine:</strong> Target <span class="highlight-blue">< 7 ¬µmol/L</span>. High levels indicate impaired methylation and increased risk of hippocampal atrophy.</li>
            <li><strong>Fasting Insulin:</strong> Target <span class="highlight-blue">< 4.5 uIU/mL</span>. Hyperinsulinemia prevents the brain from utilizing ketones and promotes amyloid accumulation.</li>
            <li><strong>Vitamin D (25-OH):</strong> Target <span class="highlight-blue">60-80 ng/mL</span>. Vitamin D is a potent neurosteroid that aids in amyloid clearance.</li>
            <li><strong>Zinc/Copper Ratio:</strong> Target <span class="highlight-blue">1.0 - 1.2</span>. Excess copper relative to zinc is linked to increased oxidative stress in the brain.</li>
        </ul>

        <div class="case-study">
            <div class="case-study-header">
                <div class="case-study-icon">üë§</div>
                <div>
                    <p class="box-label">Case Study: The "Sweet" and "Hot" Decline</p>
                    <p style="margin:0; font-size:12px; color:rgba(255,255,255,0.8)">Type 1.5 Glycotoxic MCI</p>
                </div>
            </div>
            <div class="case-study-content">
                <div class="patient-profile">
                    <div class="patient-avatar">M</div>
                    <div class="patient-info">
                        <h4>Margaret, 68</h4>
                        <p>Symptoms: Word-finding difficulties, "foggy" brain, MoCA Score: 23/30</p>
                    </div>
                </div>
                <p><strong>Initial Labs:</strong> HbA1c 5.9%, Fasting Insulin 14.2 uIU/mL, hs-CRP 3.2 mg/L, Homocysteine 12.8 ¬µmol/L. ApoE status: 3/4.</p>
                <p><strong>Intervention:</strong> Margaret was placed on the <strong>KetoFLEX 12/3</strong> protocol. We introduced methylated B-complex for homocysteine and high-dose Omega-3 (3g EPA/DHA) for inflammation. We utilized the <i>B.R.I.D.G.E. Method‚Ñ¢</i> to guide her through the transition to a fat-adapted state.</p>
                <p><strong>Outcomes:</strong> After 6 months, her MoCA score improved to 27/30. Fasting insulin dropped to 4.1 uIU/mL, and her subjective "fog" lifted entirely. Margaret reported she could "finish her own sentences again."</p>
            </div>
        </div>

        <h2 id="ketoflex">4. KetoFLEX 12/3: The Nutritional Foundation</h2>
        <p>The brain in MCI/AD often suffers from "Type 3 Diabetes"‚Äîa localized insulin resistance where neurons can no longer efficiently burn glucose. The <span class="highlight">KetoFLEX 12/3</span> framework restores metabolic flexibility by inducing mild nutritional ketosis, providing the brain with an alternative fuel source (ketones).</p>

        <h3>The Core Components:</h3>
        <ul>
            <li><strong>Keto:</strong> A plant-rich, high-fiber ketogenic diet.</li>
            <li><strong>FLEX:</strong> Metabolic flexibility; the ability to switch between burning glucose and fat.</li>
            <li><strong>12:</strong> A minimum of 12 hours of fasting between the last meal of the day and the first meal of the next day.</li>
            <li><strong>3:</strong> Ending all food consumption at least 3 hours before sleep to prevent insulin spikes during the glymphatic cleansing process.</li>
        </ul>

        <div class="alert-box info">
            <p class="alert-label">Practitioner Note</p>
            <p>For ApoE4 carriers, we prioritize <strong>monounsaturated fats</strong> (extra virgin olive oil, avocado) over saturated fats (coconut oil, butter) to prevent a paradoxical rise in LDL-p and maintain vascular integrity.</p>
        </div>

        <h2 id="apoe4">5. Individualized Care: The ApoE4 Genotype</h2>
        <p>The <strong>Apolipoprotein E (ApoE)</strong> gene is the most significant genetic risk factor for late-onset AD. Understanding a client's status is essential for <span class="highlight">Individualizing Care</span>.</p>

        <ul>
            <li><strong>ApoE3/3:</strong> Neutral risk (approx. 60-70% of population).</li>
            <li><strong>ApoE3/4:</strong> 2-3x increased risk.</li>
            <li><strong>ApoE4/4:</strong> 10-12x increased risk.</li>
        </ul>

        <p>ApoE4 is not a "death sentence"; it is an ancient gene that was advantageous in environments with high pathogen loads. In the modern world, ApoE4 carriers are more "pro-inflammatory." They hyper-absorb cholesterol and are slower to clear toxins. For these clients, we emphasize <span class="highlight-blue">heavy metal detoxification</span> and a strict avoidance of processed saturated fats.</p>

        <h2 id="guide">6. Guiding the Journey: The Non-Nutritional Pillars</h2>
        <p>The final stage of the <span class="highlight">B.R.I.D.G.E. Method‚Ñ¢</span> is <strong>Evolve & Optimize</strong>, where we address the lifestyle drivers that sustain cognitive health.</p>

        <h3>Sleep Hygiene & The Glymphatic System</h3>
        <p>During deep sleep, the glymphatic system "washes" the brain of amyloid-beta. We use wearable data (Oura, Whoop) to track <strong>Deep Sleep</strong> and <strong>REM</strong>. If a client has sleep apnea (common in Type 4/Vascular), cognitive recovery is nearly impossible without CPAP or oral appliances.</p>

        <h3>Brain Training (Neuroplasticity)</h3>
        <p>Passive activity (watching TV) is synaptoclastic. Active challenge is synaptoblastic. We recommend 20-30 minutes of daily brain training (e.g., BrainHQ) which has been clinically shown to improve processing speed and auditory memory.</p>

        <h3>Stress Management (MBSR)</h3>
        <p>Chronic cortisol elevation is toxic to the hippocampus. Mindfulness-Based Stress Reduction (MBSR) or daily meditation is a non-negotiable component of the protocol to reduce the "toxic" burden of psychological stress.</p>

        <div class="check-understanding">
            <p class="box-label">Check Your Understanding</p>
            <div class="question-item">
                <p class="question-text">1. Why is the "3" in KetoFLEX 12/3 (fasting 3 hours before bed) critical for cognitive health?</p>
                <button class="reveal-btn" onclick="this.nextElementSibling.classList.toggle('show')">Reveal Answer</button>
                <p class="answer-text">Fasting 3 hours before sleep prevents an insulin spike. High insulin inhibits the glymphatic system's ability to clear amyloid-beta and prevents the brain from entering a state of repair and autophagy during the night.</p>
            </div>

            <div class="question-item">
                <p class="question-text">2. Margaret presents with a Homocysteine of 13.5 and a Vitamin D of 22. Which AD subtypes are likely involved?</p>
                <button class="reveal-btn" onclick="this.nextElementSibling.classList.toggle('show')">Reveal Answer</button>
                <p class="answer-text">This suggests a combination of Type 1 (Inflammatory - high homocysteine) and Type 2 (Atrophic - low Vitamin D trophic support).</p>
            </div>
        </div>

        <div class="takeaways-box">
            <p class="box-label">Key Takeaways</p>
            <ul>
                <li>Cognitive decline is a <strong>multifactorial metabolic imbalance</strong>, not a single-pathogen disease.</li>
                <li>The Bredesen Protocol aims for <strong>synaptoblastic signaling</strong> by "patching" 36+ metabolic holes.</li>
                <li><strong>Data-Driven Decision</strong> targets are much stricter than conventional ranges (e.g., Insulin < 4.5).</li>
                <li><strong>ApoE4 status</strong> dictates the type of fats used in the ketogenic framework.</li>
                <li>Success requires <strong>Guiding the Journey</strong> through sleep, stress, and cognitive stimulation.</li>
            </ul>
        </div>

        <div class="references-box">
            <h4>References & Further Reading</h4>
            <ul class="references-list">
                <li>Bredesen, D. E. et al. (2022). "Precision Medicine Approach to Alzheimer‚Äôs Disease: A Prospective Clinical Trial." <i>Journal of Alzheimer's Disease</i>.</li>
                <li>Rao, R. V. et al. (2021). "Reversal of Cognitive Decline: 100 Patients." <i>Journal of Alzheimer‚Äôs Disease & Parkinsonism</i>.</li>
                <li>Norwitz, N. G. et al. (2019). "The Ketogenic Diet's Role in Alzheimer's Disease." <i>Frontiers in Aging Neuroscience</i>.</li>
                <li>Bredesen, D. E. (2017). <i>The End of Alzheimer's: The First Program to Prevent and Reverse Cognitive Decline</i>. Avery Publishing.</li>
                <li>Toups, K. et al. (2022). "Precision Medicine Management of Early Alzheimer‚Äôs Disease." <i>Journal of Personalized Medicine</i>.</li>
            </ul>
        </div>

        <footer class="lesson-footer">
            <img src="https://accredipro.com/wp-content/uploads/2023/05/AccrediPro-Logo-Horizontal-1.png" alt="AccrediPro Academy" class="footer-logo">
            <p class="brand">AccrediPro Academy Certified Integrative Medicine Practitioner</p>
            <p class="copyright">&copy; 2024 AccrediPro Academy. All rights reserved. Confidential Professional Certification Material.</p>
        </footer>
    </div>
</body>

</html>